HH Biotechnology Holdings Company
HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics. The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016. HH Biotechnology Holdings Company was incorpora… Read more
HH Biotechnology Holdings Company (HHBT) - Net Assets
Latest net assets as of September 2016: $29.60 Million USD
Based on the latest financial reports, HH Biotechnology Holdings Company (HHBT) has net assets worth $29.60 Million USD as of September 2016.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($42.75 Million) and total liabilities ($13.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $29.60 Million |
| % of Total Assets | 69.24% |
| Annual Growth Rate | 4.13% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 29.27 |
HH Biotechnology Holdings Company - Net Assets Trend (2012–2015)
This chart illustrates how HH Biotechnology Holdings Company's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HH Biotechnology Holdings Company (2012–2015)
The table below shows the annual net assets of HH Biotechnology Holdings Company from 2012 to 2015.
| Year | Net Assets | Change |
|---|---|---|
| 2015-12-31 | $28.36 Million | +48.19% |
| 2014-12-31 | $19.14 Million | -20.30% |
| 2013-12-31 | $24.01 Million | -4.41% |
| 2012-12-31 | $25.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HH Biotechnology Holdings Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2015)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $11.77 Million | 41.72% |
| Common Stock | $14.06K | 0.05% |
| Other Comprehensive Income | $12.12 Million | 42.96% |
| Other Components | $4.31 Million | 15.27% |
| Total Equity | $28.22 Million | 100.00% |
HH Biotechnology Holdings Company Competitors by Market Cap
The table below lists competitors of HH Biotechnology Holdings Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fashion Bel Air S.A
PA:ALFBA
|
$270.95 |
|
Universal Media Group Inc
PINK:UMGP
|
$271.05 |
|
Healixa Inc
PINK:EMOR
|
$271.29 |
|
EGUVF
PINK:EGUVF
|
$271.44 |
|
BAKRIE SUMATERA PL
BE:OSW
|
$270.27 |
|
Hoshi Resource Corp.
V:HRC-P
|
$270.21 |
|
BlackRock American Income Trust Ord
LSE:BRAI
|
$269.38 |
|
JPMORGAN EMERGING EUROPE MIDDLE EAST & AFRICA SECURITIES PLCc
LSE:JEMA
|
$269.32 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HH Biotechnology Holdings Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2014 to 2015, total equity changed from 19,136,501 to 28,216,190, a change of 9,079,689 (47.4%).
- Net income of 2,476,265 contributed positively to equity growth.
- Share repurchases of 4,493 reduced equity.
- Other comprehensive income increased equity by 12,121,916.
- Other factors decreased equity by 5,513,999.
Equity Change Factors (2014 to 2015)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.48 Million | +8.78% |
| Share Repurchases | $4.49K | -0.02% |
| Other Comprehensive Income | $12.12 Million | +42.96% |
| Other Changes | $-5.51 Million | -19.54% |
| Total Change | $- | 47.45% |
Book Value vs Market Value Analysis
This analysis compares HH Biotechnology Holdings Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $0.00 | $0.00 | x |
| 2015-12-31 | $2.09 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HH Biotechnology Holdings Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.78%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.99%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.65x
- Recent ROE (8.78%) is above the historical average (-7.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -9.26% | -31.65% | 0.12x | 2.37x | $-4.84 Million |
| 2013 | -7.56% | -23.58% | 0.13x | 2.48x | $-4.22 Million |
| 2014 | -22.54% | -54.01% | 0.15x | 2.82x | $-6.23 Million |
| 2015 | 8.78% | 30.99% | 0.17x | 1.65x | $-345.35K |
Industry Comparison
This section compares HH Biotechnology Holdings Company's net assets metrics with peer companies in the Real Estate Services industry.
Industry Context
- Industry: Real Estate Services
- Average net assets among peers: $860,434,363
- Average return on equity (ROE) among peers: -17.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HH Biotechnology Holdings Company (HHBT) | $29.60 Million | -9.26% | 0.44x | $270.33 |
| Aroundtown SA (AANNF) | $2.43 Billion | 28.32% | 0.83x | $1.42 Billion |
| AAP Inc (AAPJ) | $-1.00 Million | 0.00% | 0.00x | $1.97 |
| Ambase Corp (ABCP) | $-4.12 Million | 0.00% | 0.00x | $6.43 Million |
| Americann Inc (ACAN) | $1.31 Million | -131.48% | 2.04x | $2.44K |
| Ascendas India Trust (ACNDF) | $1.32 Billion | 9.88% | 1.00x | $831.45 Million |
| Adler Group S.A (ADPPF) | $2.20 Billion | 17.61% | 0.90x | $41.80 Million |
| Agritek Holdings Inc (AGTK) | $487.65K | -21.43% | -0.50x | $5.39K |
| reAlpha Tech Corp. Common Stock (AIRE) | $13.17 Million | -41.42% | 0.60x | $32.30 Million |
| Avalon GloboCare Corp. (ALBT) | $7.31 Million | -47.40% | 0.73x | $2.25 Million |
| Allreal (ALRHF) | $2.64 Billion | 8.00% | 1.23x | $2.39 Billion |